PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe

Yokohama, Japan, & San Carlos, California, USA - REPROCELL, Inc., and NeuCyte, Inc., today announced a new distributorship.

Although NeuCyte has direct sales in North America, this new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements. These components come in kit formats so the user can set up well-defined, highly functional in vitro co-culture systems for compound screening, disease modeling and neurotoxicity assessment.

Continue reading 

PRESS RELEASE: ABLE Biott Bioreactors now available in Europe

The lab-scale system will allow researchers to study and culture stem cells in suspension

Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.

We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.

Continue reading 

Pluripotent Potential for Clinical Application

Since their development in the mid-2000s, the versatile nature of induced Pluripotent Stem Cells (iPSCs) has unlocked the potential of curative approaches instead of symptom-reactive treatments. In particular, fields which deal with genetic disorders and regenerative therapies would benefit from this. The advancement of iPSC technology compliments the advent of personalized medicine, allowing for a future where individuals could be treated using autologous iPSCs.

Continue reading 

Stem Cells for Autism

In this post, we highlight recent advancements in stem cells as treatment and study of autism to commemorate World Autism Awareness Day (2 April 2019).

Autism spectrum disorder (ASD) is a complex developmental disability that impairs the ability to communicate and relate to others. Affecting 1% of the world population, it is the most commonly diagnosed childhood developmental disorder. In 2018, Centers for Disease Control (CDC) reported that rates of autism had increased to an estimated 1 in 59 children, up from 1 in 88 just six years ago.

Continue reading 

Spotlight: StemRNA Neuro iPSCs – Human Brain Neurons for Functional Assays

Human induced pluripotent stem cell (iPSCs) derived  neural models to study brain disease provide an unlimited resource for disease modelling as well as being a tool for drug screening for effective therapies. The limited access to viable patient neurons from brain tissue itself generates the need for functional and reproducible human neuron cell models. Such cells are now increasingly used for drug development studies as well as supporting research into mechanisms and pathways of various neurological diseases.

Continue reading 

Using human iPSCs as an in vitro model for regenerative medicine, drug screening and disease modelling

In translational medicine, research using primary patient samples is advantageous over cell lines as the expression of the protein under investigation is regulated by native elements in primary samples.

Continue reading 

Tissue Sourcing for the Development of iPSC-derived Disease Models

Human induced pluripotent stem cells (iPSCs)-based models are an ideal resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by drug treatment[3]. Such iPSC-based models enable studies to be performed under defined experimental conditions and in a reproducible manner.

Continue reading 

Press Release: ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

Funding will be used to improve efficiency of induced pluripotent stem cell production

Continue reading 

Join REPROCELL at ISSCR 2018 in Melbourne, Australia

ISSCR (the International Society for Stem Cell Research) is the preeminent stem cell research group in the world. ISSCR is holding its 2018 Annual Meeting in Melbourne, Australia – and REPROCELL will be there.

Join us 20-23 June at booth 74 and learn how we can help you with your stem cell needs.

Continue reading 

REPROCELL’s footprint extends to serve life sciences in India

REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.

Continue reading